AMHERST, Mass. — Having established the effectiveness of her nanoparticle drug-delivery system for cancer immunotherapy, University of Massachusetts Amherst researcher Prabhani Atukorale, has been awarded $2.5 million from the National Institutes of Health to broaden the scope of her vaccine research to include treating those with active cancer.

In a new study, researchers describe the development and validation of a multi-ancestry polygenic risk score (PRS) for AD that performs much better than previously constructed ones, especially for genetically diverse groups. This expanded representation of population groups is crucial for developing more robust and universally applicable PRS models, which can improve risk prediction among an ancestrally diverse group of patients.